LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CP724714 | 0.12 | uM | LJP5 | 1 | A11 | 72 | hr | 1476 | 2199 | 3694 | 0.5953 | 0.3257 |
| SK-BR-3 | CP724714 | 0.12 | uM | LJP5 | 2 | A11 | 72 | hr | 1476 | 2036 | 3694 | 0.5512 | 0.2522 |
| SK-BR-3 | CP724714 | 0.12 | uM | LJP5 | 3 | A11 | 72 | hr | 1476 | 2019 | 3694 | 0.5466 | 0.2446 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 1 | I11 | 72 | hr | 1476 | 4167 | 3694 | 1.1280 | 1.2133 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 2 | I11 | 72 | hr | 1476 | 4037 | 3694 | 1.0928 | 1.1547 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 3 | I11 | 72 | hr | 1476 | 3751 | 3694 | 1.0154 | 1.0257 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 1 | A23 | 72 | hr | 1476 | 3191 | 3694 | 0.8638 | 0.7731 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 2 | A23 | 72 | hr | 1476 | 3343 | 3694 | 0.9050 | 0.8417 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 3 | A23 | 72 | hr | 1476 | 3076 | 3694 | 0.8327 | 0.7213 |
| SK-BR-3 | Momelotinib | 0.12 | uM | LJP5 | 1 | P11 | 72 | hr | 1476 | 3104 | 3694 | 0.8403 | 0.7339 |
| SK-BR-3 | Momelotinib | 0.12 | uM | LJP5 | 2 | P11 | 72 | hr | 1476 | 3055 | 3694 | 0.8270 | 0.7118 |
| SK-BR-3 | Momelotinib | 0.12 | uM | LJP5 | 3 | P11 | 72 | hr | 1476 | 2617 | 3694 | 0.7084 | 0.5143 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP5 | 1 | D05 | 72 | hr | 1476 | 3746 | 3694 | 1.0141 | 1.0234 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP5 | 2 | D05 | 72 | hr | 1476 | 3695 | 3694 | 1.0003 | 1.0004 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP5 | 3 | D05 | 72 | hr | 1476 | 3868 | 3694 | 1.0471 | 1.0784 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP6 | 1 | I05 | 72 | hr | 1476 | 3106 | 3694 | 0.8408 | 0.7348 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP6 | 2 | I05 | 72 | hr | 1476 | 3838 | 3694 | 1.0390 | 1.0649 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP6 | 3 | I05 | 72 | hr | 1476 | 3139 | 3694 | 0.8497 | 0.7497 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 1 | E23 | 72 | hr | 1476 | 3073 | 3694 | 0.8319 | 0.7199 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 2 | E23 | 72 | hr | 1476 | 2867 | 3694 | 0.7761 | 0.6270 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 3 | E23 | 72 | hr | 1476 | 2514 | 3694 | 0.6806 | 0.4678 |
| SK-BR-3 | Enzastaurin | 0.12 | uM | LJP5 | 1 | D17 | 72 | hr | 1476 | 3967 | 3694 | 1.0739 | 1.1231 |
| SK-BR-3 | Enzastaurin | 0.12 | uM | LJP5 | 2 | D17 | 72 | hr | 1476 | 4271 | 3694 | 1.1562 | 1.2602 |
| SK-BR-3 | Enzastaurin | 0.12 | uM | LJP5 | 3 | D17 | 72 | hr | 1476 | 4377 | 3694 | 1.1849 | 1.3080 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 1 | M23 | 72 | hr | 1476 | 3439 | 3694 | 0.9310 | 0.8850 |